武汉回盛生物科技股份有限公司 独立董事 2024 年度述职报告 才学鹏 各位股东及股东代表： 本人作为公司独立董事，2024 年度严格按照《公司法》《证券法》《上 市公司独立董事管理办法》《深圳证券交易所创业板股票上市规则》（以下简 称《股票上市规则》）等法律法规及规范性文件的有关规定，认真履行《公司 章程》《独立董事工作制度》赋予的职责，忠实、勤勉、独立地履职，充分发 挥独立董事的作用，维护全体股东尤其是中小股东的利益。现将本人 2024 年 度履职情况汇报如下： 一、独立董事的基本情况 本人才学鹏，出生于 1958 年，中国国籍，无境外永久居留权，博士研究 生学历，研究员。历任中国农业科学院兰州兽医研究所所长、党委书记，中农 威特生物科技股份有限公司董事长、总经理，中国动物疫病预防控制中心主任， 中国兽医药品监察所所长，党委副书记，中国兽药协会会长。现任瑞普生物股 份有限公司独立董事。自 2024 年 3 月至今担任公司独立董事。 在担任公司独立董事期间，本人未在公司担任除独立董事以外的任何职 务，也未在公司主要股东公司担任任何职务，与公司以及主要股东之间不存在 妨碍本人进行独立客观判断的关系，不存在影响 ...

各位股东及股东代表： 本人作为公司独立董事，2024 年度严格按照《公司法》《证券法》《上 市公司独立董事管理办法》《深圳证券交易所创业板股票上市规则》等法律法 规及规范性文件的有关规定，认真履行《公司章程》《独立董事工作制度》赋 予的职责，忠实、勤勉、独立地履职，充分发挥独立董事的作用，维护全体股 东尤其是中小股东的利益。现将本人 2024 年度履职情况汇报如下： 一、独立董事的基本情况 本人曾振灵，男，1963 年出生，中国国籍，兽医药理学与毒理学博士研 究生学历，教授职称，无境外永久居留权。历任华南农业大学教员、讲师、副 教授、教授，现任华南农业大学兽医学院二级岗教授。自 2016 年 12 月起担任 公司独立董事，于 2024 年 3 月离任。 在担任公司独立董事期间，本人未在公司担任除独立董事以外的任何职 务，也未在公司主要股东公司担任任何职务，与公司以及主要股东之间不存在 妨碍本人进行独立客观判断的关系，不存在影响独立董事独立性的情况，符合 《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》中对独立董事独立性的相关要求。 武汉回盛生物科技股份有限 ...

武汉回盛生物科技股份有限公司 2024 年度独立董事述职报告 谢获宝 （已离职） 各位股东及股东代表： 本人作为公司独立董事，2024 年度严格按照《公司法》《证券法》《上 市公司独立董事管理办法》《深圳证券交易所创业板股票上市规则》等法律法 规及规范性文件的有关规定，认真履行《公司章程》《独立董事工作制度》赋 予的职责，忠实、勤勉、独立地履职，充分发挥独立董事的作用，维护全体股 东尤其是中小股东的利益。现将本人 2024 年度履职情况汇报如下： 一、独立董事的基本情况 本人谢获宝，男，1967 年出生，中国国籍，经济学博士研究生学历，教 授，无境外永久居留权。现任武汉大学经济与管理学院会计学教授，博士研究 生导师，多年从事会计学科研、教学工作，具备丰富的会计专业知识和经验。 兼任上市公司广州金域医学检验集团股份有限公司、杰克科技股份有限公司独 立董事；非上市公司弘毅远方基金管理有限公司、湖北融通高科先进材料集团 股份有限公司、湖北金龙新材料股份有限公司、湖北交投资本投资有限公司独 立董事。自 2016 年 12 月起担任公司独立董事，于 2024 年 3 月离任。 在担任公司独立董事期间，本人未在公司担任除 ...

各位股东及股东代表： 本人作为公司独立董事，2024 年度严格按照《公司法》《证券法》《上 市公司独立董事管理办法》《深圳证券交易所创业板股票上市规则》（以下简 称《股票上市规则》）等法律法规及规范性文件的有关规定，认真履行《公司 章程》《独立董事工作制度》赋予的职责，忠实、勤勉、独立地履职，充分发 挥独立董事的作用，维护全体股东尤其是中小股东的利益。现将本人 2024 年 度履职情况汇报如下： 武汉回盛生物科技股份有限公司 独立董事 2024 年度述职报告 冉明东 一、独立董事的基本情况 本人冉明东，男，1975 年出生，中国国籍，会计学博士。曾担任中南财 经政法大学副教授、武汉光迅科技股份有限公司独立董事。现任中南财经政法 大学会计学院副院长、教授，武汉海特生物制药股份有限公司、武汉回盛生物 科技股份有限公司独立董事。 在担任公司独立董事期间，本人未在公司担任除独立董事以外的任何职 务，也未在公司主要股东公司担任任何职务，与公司以及主要股东之间不存在 妨碍本人进行独立客观判断的关系，不存在影响独立董事独立性的情况，符合 《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上 ...

回盛生物（300871）公告，2024年营业收入12亿元，同比增长17.71%。归属于上市公司股东的净亏损 2015.56万元，去年同期净利润1678.08万元，由盈转亏。公司经本次董事会审议通过的利润分配预案 为：以2024年12月31日总股本1.66亿股剔除存放于回购专用证券账户75.36万股后的总股本1.65亿股为基 数，向全体股东每10股派发现金红利1.3元(含税)，送红股0股(含税)，以资本公积金向全体股东每10股 转增0股。 ...

Financial Performance - The company's net profit attributable to shareholders decreased by 220.11% year-on-year, while the net profit after deducting non-recurring gains and losses fell by 45.06%[4]. - The company's operating revenue for 2024 reached ¥1,200,327,933.81, an increase of 17.71% compared to ¥1,019,758,798.36 in 2023[23]. - The net profit attributable to shareholders was a loss of ¥20,155,591.43 in 2024, a decline of 220.11% from a profit of ¥16,780,818.77 in 2023[23]. - The net cash flow from operating activities decreased by 53.15% to ¥43,531,846.81 in 2024, down from ¥92,919,346.00 in 2023[23]. - The total assets at the end of 2024 were ¥3,014,682,865.02, reflecting a 1.32% increase from ¥2,975,460,462.12 at the end of 2023[24]. - The net assets attributable to shareholders decreased by 3.43% to ¥1,457,576,824.02 at the end of 2024, compared to ¥1,509,281,062.12 at the end of 2023[24]. - The company reported a basic earnings per share of -¥0.1215 for 2024, a decrease of 220.18% from ¥0.1011 in 2023[23]. - The company achieved operating revenue of 1,200.33 million yuan, an increase of 17.71% compared to the same period last year[50]. - The net profit attributable to shareholders was -20.16 million yuan, a decrease of 220.11% year-on-year[50]. Research and Development - The company increased its R&D expenses by a significant margin, impacting net profit due to ongoing investments in innovation[4]. - The company plans to continue its focus on R&D for new products and technologies to enhance market competitiveness[32]. - Research and development expenses increased by 25.11% to ¥55,797,216.51, reflecting a higher investment in innovation[77]. - The company is actively developing new products, with an investment of $10 million in R&D for innovative veterinary pharmaceuticals[131]. - The company is focusing on developing functional pet health products, with plans to launch 10 new products and establish a comprehensive sales network[79]. Market Expansion and Strategy - The company aims to expand its overseas market presence as part of its "going out" strategy to mitigate domestic business cycle impacts[5]. - The company is exploring market expansion opportunities and potential mergers and acquisitions to drive future growth[32]. - The company is implementing a "going out" strategy to expand overseas markets and reduce the cyclical impact of domestic business[40]. - The company is focusing on expanding its production capacity and enhancing its product offerings to adapt to market changes and improve profitability[108]. - Market expansion efforts include entering three new regional markets, aiming for a 25% increase in market share by the end of 2025[132]. Product Development and Offerings - The company plans to enhance its product competitiveness by focusing on the development of new veterinary drugs and optimizing its product performance and supply chain structure[5]. - The company has obtained 188 veterinary drug approval numbers, with products widely used in various fields including pigs, poultry, aquaculture, ruminants, and pets[42]. - The company launched 3 new drug approvals and 7 new veterinary drugs during the reporting period, expanding its product offerings significantly[61]. - The company’s pet product line expanded significantly, with 7 new pet product approvals obtained during the reporting period[53]. Financial Management and Investments - The company raised a total of RMB 154,001 million through its initial public offering and convertible bonds, with a net amount of RMB 154,001 million as of December 31, 2024[100]. - The company has invested RMB 48,587.17 million in fundraising projects and RMB 17,006.59 million in working capital from the RMB 68,929.90 million raised through convertible bonds[101]. - The company has achieved a project investment progress of 99.91% for the new base construction project for automated production of premix agents, with a total commitment of RMB 32,000 million[105]. - The company has completed 100% of the investment for the construction of the quality inspection center project, with a total commitment of RMB 7,000 million[105]. - The company has initiated the construction of a comprehensive production line for pet preparations, with a total commitment of RMB 9,000 million, achieving 100% of the investment progress[105]. Governance and Compliance - The governance structure remains robust, with compliance to all relevant laws and regulations, ensuring transparency and accountability[129]. - The company maintains complete operational independence from its controlling shareholders, ensuring no conflicts of interest in decision-making processes[130]. - The company has a structured remuneration decision process based on performance, capability, and responsibilities[151]. - The company is focused on governance improvements and compliance with regulatory requirements following recent board changes[141]. - The board strictly adhered to regulations and focused on the interests of minority shareholders, ensuring compliance and prudent accounting practices[158]. Environmental Responsibility - The company strictly complies with multiple environmental protection laws and standards, including the Environmental Protection Law and the Air Pollution Prevention and Control Law[193]. - The company has implemented a comprehensive wastewater treatment system, including multiple treatment processes to meet discharge standards[196]. - Emission standards for waste gas are met, with all processes equipped with specialized treatment devices to ensure compliance with national air quality standards[197]. - The company has established a comprehensive environmental management system to minimize pollution and ensure compliance with environmental regulations[193]. Employee Management and Development - The total number of employees at the end of the reporting period is 1,028, with 393 in the parent company and 622 in major subsidiaries[164]. - The company has a structured salary system that includes basic salary, performance bonuses, and project incentives, focusing on employee contributions and industry salary levels[166]. - The company emphasizes employee training with a diverse training system, including internal and external training tailored to different job roles[167]. - The company has established a performance evaluation system to motivate employees and ensure compliance with labor laws[166]. Shareholder Engagement and Dividends - The company has a cash dividend policy that prioritizes cash distributions over stock dividends, considering cash flow and business growth[169]. - The company approved a cash dividend of RMB 2.70 per 10 shares (including tax), totaling RMB 44,552,853.90 for the 2023 fiscal year[170]. - The cash dividend distribution is based on a total share capital of 165,012,035 shares, with a cash dividend amount of RMB 21,451,564.55 (including tax) for the current reporting period[173]. - The company plans to distribute a cash dividend of RMB 1.30 per 10 shares (including tax) for the 2024 fiscal year, pending approval at the 2024 annual general meeting[175].

Financial Performance - The company's revenue for Q1 2025 reached ¥399,068,578.25, representing a 92.96% increase compared to ¥206,809,092.09 in the same period last year[5] - Net profit attributable to shareholders was ¥44,496,959.41, a significant turnaround from a loss of ¥16,405,616.80, marking a 371.23% increase[5] - Basic earnings per share rose to ¥0.2684 from a loss of ¥0.0989, indicating a 371.39% improvement[5] - Total operating revenue for the current period reached ¥399,068,578.25, a significant increase from ¥206,809,092.09 in the previous period, representing a growth of approximately 92.7%[26] - Net profit for the current period was ¥44,777,497.12, a turnaround from a net loss of ¥16,405,616.80 in the previous period[28] - Earnings per share (EPS) for the current period was ¥0.2684, compared to a loss per share of ¥0.0989 in the prior period[29] Cash Flow - The net cash flow from operating activities improved to ¥57,960,264.16, compared to a negative cash flow of ¥46,279,493.65 in the previous year, reflecting a 225.24% increase[5] - Cash inflow from operating activities totaled ¥332,255,252.14, up from ¥224,327,944.23 in the previous period, reflecting a growth of approximately 48.2%[29] - The cash flow from operating activities showed resilience despite challenges in investment and financing activities, highlighting operational strength[30] - The company continues to focus on managing cash flows effectively amid fluctuating investment returns and financing conditions[30] Assets and Liabilities - Total assets increased by 1.04% to ¥3,046,149,776.08 from ¥3,014,682,865.02 at the end of the previous year[5] - Total current assets increased to ¥1,346,009,223.51 from ¥1,312,585,417.22, reflecting a growth of about 2.5%[22] - Total liabilities decreased to ¥1,461,121,229.57 from ¥1,549,479,748.16, a reduction of about 5.7%[24] - Total equity increased to ¥1,585,028,546.51 from ¥1,465,203,116.86, representing a growth of approximately 8.2%[24] - The company’s total non-current liabilities decreased to ¥513,027,212.71 from ¥626,164,645.33, a decline of approximately 18.1%[24] Investment and Financing Activities - The company reported a significant increase in investment income, with a fair value change gain of ¥8,711,382.63, compared to a loss of ¥18,092,751.86 in the previous year, marking a 148.15% improvement[12] - Total cash inflow from investment activities was $96,164,407.02, down from $183,452,284.70, while cash outflow for investment activities was $223,629,940.01, resulting in a net cash flow of -$127,465,532.99, worsening from -$76,332,192.37[30] - Cash inflow from financing activities totaled $124,116,220.00, a decrease from $202,776,473.00, while cash outflow was $87,759,468.86, down from $107,572,170.13, leading to a net cash flow of $36,356,751.14, compared to $95,204,302.87 previously[30] Shareholder Information - The total number of common shareholders at the end of the reporting period is 14,229[16] - Wuhan Tongsheng Investment Co., Ltd. holds 48.38% of shares, totaling 82,800,000 shares, with 6,200,000 shares pledged[16] Future Plans and Management - The company plans to continue expanding its product sales, which significantly contributed to the revenue growth in the current quarter[12] - The company has triggered the conditional redemption clause for the "Hui Sheng Convertible Bonds" due to stock price conditions being met[18] - The company plans to exercise its right for early redemption of the convertible bonds, as approved by the board of directors[18] - The company plans to implement new accounting standards starting in 2025, which may impact future financial reporting[32] - The board of directors remains committed to strategic financial management to enhance shareholder value and operational efficiency[33] Other Financial Metrics - The company experienced a 238.42% increase in taxes payable, amounting to ¥9,545,304.92, primarily due to increased corporate income tax and VAT[11] - The company reported accounts receivable of ¥415,047,080.15, an increase from ¥368,367,475.80, representing a growth of about 12.6%[21] - The company’s inventory decreased slightly to ¥244,328,189.32 from ¥248,164,158.72, a decline of approximately 1.5%[21] - The company’s fixed assets decreased to ¥1,505,027,290.50 from ¥1,525,198,068.46, a reduction of about 1.3%[22] - The company’s cash and cash equivalents decreased to ¥271,699,911.85 from ¥326,144,663.23, a decline of approximately 16.7%[21] - The ending balance of cash and cash equivalents was $151,847,660.83, down from $201,749,381.84, reflecting a decrease in liquidity[31] - The company reported a total cash outflow of $32,744,282.41 for the period, which is a slight increase from the previous outflow of $27,762,907.55[31] - The company has not yet audited its first-quarter report, indicating that the financial results are still subject to review[32]

我们接受委托，对后附的武汉回盛生物科技股份有限公司（以下简称"回盛生物"）截至 2024 年 12 月 31 日止的《关于前次募集资金使用情况的报告》执行了鉴证工作。 按照中国证券监督管理委员会印发的《监管规则适用指引——发行类第 7 号》的规定， 编制《关于前次募集资金使用情况的报告》并保证其内容真实、准确、完整，不存在虚假记 载、误导性陈述或重大遗漏，以及为我们的鉴证工作提供真实、合法、完整的实物证据、原 始书面材料、副本材料、口头证言以及我们认为必要的其他证据，是回盛生物董事会的责任。 我们的责任是在执行鉴证工作的基础上，对《关于前次募集资金使用情况的报告》提出鉴证 结论。 我们按照《中国注册会计师其他鉴证业务准则第 3101 号——历史财务信息审计或审阅 以外的鉴证业务》的规定执行了鉴证工作，该准则要求我们遵守中国注册会计师职业道德守 则，计划和执行鉴证工作以对《关于前次募集资金使用情况的报告》是否不存在重大错报获 取合理保证。在鉴证过程中，我们实施了抽查会计记录、重新计算相关项目金额等我们认为 必要的程序。我们相信，我们的鉴证工作为提出鉴证结论提供了合理的基础。 我们认为，后附的武汉回盛生物科技股份 ...

武汉回盛生物科技股份有限公司 2024 年度内部控制自我评价报告 武汉回盛生物科技股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定以及《深圳证券交易所上市公 司自律监管指引第 2 号——创业板上市公司规范运作》等法律法规和规章制度的要求， 结合武汉回盛生物科技股份有限公司（以下简称"公司"）内部控制制度和评价方法， 在内部控制日常监督和专项监督的基础上，我们对公司 2024 年 12 月 31 日（内部控制 评价报告基准日）的内部控制有效性进行了评价。 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性， 并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控 制进行监督。经理层负责组织领导企业内部控制的日常运行。公司董事会、监事会及董 事、监事、高级管理人员保证本报告内容不存在任何虚假记载、误导性陈述或重大遗漏， 并对本报告内容的真实性、准确性和完整性承担个别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信 息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限 性 ...

武汉回盛生物科技股份有限公司 证券代码：300871 证券简称：回盛生物 公告编号：2025-037 转债代码：123132 转债简称：回盛转债 关于续聘2025年度审计机构的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、董事会、审计委员会对拟续聘会计师事务所不存在异议； 2、本次续聘会计师事务所符合财政部、国务院国资委、证监会印发的《国 有企业、上市公司选聘会计师事务所管理办法》（财会〔2023〕4 号）的规定。 武汉回盛生物科技股份有限公司（以下简称"公司"或"回盛生物"）于 2025 年 4 月 28 日召开第三届董事会第二十二次会议，审议通过了《关于续聘 2025 年度审计机构的议案》，同意续聘中审众环会计师事务所（特殊普通合 伙）（以下简称"中审众环"）为公司 2025 年度审计机构，聘期一年。该事 项尚需提交公司 2024 年年度股东大会审议，现将相关事项公告如下： 一、拟续聘会计师事务所的基本情况 （一）机构信息 1、基本信息 （1）机构名称：中审众环会计师事务所（特殊普通合伙） （2）成立日期：中审众环始创于 1987 ...